FDA approves Ruxolitinib (Opzelura) for Vitiligo Therapy: A breakthrough in the field of dermatology

The Food and Drug Administration (FDA) has authorized Ruxolitinib (Opzelura), as first at-home treatment for non-segmental vitiligo, an autoimmune condition that causes spots and patches of paler skin. Previously, it was used to treat atopic dermatitis, myelofibrosis, essential thrombocythemia, and...

Descripción completa

Detalles Bibliográficos
Autores principales: Sheikh, Ayesha, Rafique, Warisha, Owais, Rabia, Malik, Farheen, Ali, Eman
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2022
Materias:
Short Communication
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9486756/
https://www.ncbi.nlm.nih.gov/pubmed/36147080
http://dx.doi.org/10.1016/j.amsu.2022.104499

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9486756/
https://www.ncbi.nlm.nih.gov/pubmed/36147080
http://dx.doi.org/10.1016/j.amsu.2022.104499

Ejemplares similares